ICE COLD ERIC--International collaborative effort on chronic obstructive lung disease: exacerbation risk index cohorts--study protocol for an international COPD cohort study

Lara Siebeling, Gerben ter Riet, Willem M van der Wal, Ronald B Geskus, Marco Zoller, Patrick Muggensturm, Irena Joleska, Milo A Puhan, Lara Siebeling, Gerben ter Riet, Willem M van der Wal, Ronald B Geskus, Marco Zoller, Patrick Muggensturm, Irena Joleska, Milo A Puhan

Abstract

Background: Chronic Obstructive Pulmonary Disease (COPD) is a systemic disease; morbidity and mortality due to COPD are on the increase, and it has great impact on patients' lives. Most COPD patients are managed by general practitioners (GP). Too often, GPs base their initial assessment of patient's disease severity mainly on lung function. However, lung function correlates poorly with COPD-specific health-related quality of life and exacerbation frequency. A validated COPD disease risk index that better represents the clinical manifestations of COPD and is feasible in primary care seems to be useful. The objective of this study is to develop and validate a practical COPD disease risk index that predicts the clinical course of COPD in primary care patients with GOLD stages 2-4.

Methods/design: We will conduct 2 linked prospective cohort studies with COPD patients from GPs in Switzerland and the Netherlands. We will perform a baseline assessment including detailed patient history, questionnaires, lung function, history of exacerbations, measurement of exercise capacity and blood sampling. During the follow-up of at least 2 years, we will update the patients' profile by registering exacerbations, health-related quality of life and any changes in the use of medication. The primary outcome will be health-related quality of life. Secondary outcomes will be exacerbation frequency and mortality. Using multivariable regression analysis, we will identify the best combination of variables predicting these outcomes over one and two years and, depending on funding, even more years.

Discussion: Despite the diversity of clinical manifestations and available treatments, assessment and management today do not reflect the multifaceted character of the disease. This is in contrast to preventive cardiology where, nowadays, the treatment in primary care is based on patient-specific and fairly refined cardiovascular risk profile corresponding to differences in prognosis. After completion of this study, we will have a practical COPD-disease risk index that predicts the clinical course of COPD in primary care patients with GOLD stages 2-4. In a second step we will incorporate evidence-based treatment effects into this model, such that the instrument may guide physicians in selecting treatment based on the individual patients' prognosis.

Trial registration: ClinicalTrials.gov Archive NCT00706602.

Figures

Figure 1
Figure 1
Cardiovascular (CV) risk assessment and treatment choice; based on several parameters, patients fall into a specific colored box (details are illegible) and the color corresponds to a risk profile (green = low risk, orange = medium risk and red = high risk). According to that risk profile, treatment recommendation(s) are given.
Figure 2
Figure 2
COPD exacerbation risk assessment and treatment choice (example); based on several parameters, patients fall into a specific risk profile (green = low risk, orange = medium risk and red = high risk). According to that risk profile, treatment advice(s) are given.
Figure 3
Figure 3
flow chart.

References

    1. Rothman AA, Wagner EH. Chronic illness management: what is the role of primary care? Ann Intern Med. 2003;138:256–261.
    1. American Thoracic Society and European Respiratory Society Standards for the diagnosis and treatment of patients with chronic obstructive pulmonary disease. 2006.
    1. Decramer M, Bartsch P, Pauwels R, Yernault JC. Management of COPD according to guidelines. A national survey among Belgian physicians. Monaldi Arch Chest Dis. 2003;59:62–80.
    1. Fritsch K, Jacot ML, Klarer A, Wick F, Bruggmann P, Krause M, et al. Adherence to the Swiss guidelines for management of COPD: experience of a Swiss teaching hospital. Swiss Med Wkly. 2005;135:116–121.
    1. Puhan MA, Zoller M, ter RG. COPD: more than respiratory. Lancet. 2008;371:27–28. doi: 10.1016/S0140-6736(08)60064-1.
    1. Rutschmann OT, Janssens JP, Vermeulen B, Sarasin FP. Knowledge of guidelines for the management of COPD: a survey of primary care physicians. Respir Med. 2004;98:932–937. doi: 10.1016/j.rmed.2004.03.018.
    1. Puhan MA, Bachmann LM, Kleijnen J, ter Riet G, Kessels AG. Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Med. 2009;7:2. doi: 10.1186/1741-7015-7-2.
    1. Suissa S, McGhan R, Niewoehner D, Make B. Inhaled corticosteroids in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2007;4:535–542. doi: 10.1513/pats.200701-024FM.
    1. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 1999;353:1819–1823. doi: 10.1016/S0140-6736(98)10019-3.
    1. Cranston JM, Crockett AJ, Moss JR, Alpers JH. Domiciliary oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005:CD001744.
    1. Lacasse Y, Goldstein R, Lasserson TJ, Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006:CD003793.
    1. Donaldson GC, Wilkinson TM, Hurst JR, Perera WR, Wedzicha JA. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171:446–452. doi: 10.1164/rccm.200408-1054OC.
    1. Osman IM, Godden DJ, Friend JA, Legge JS, Douglas JG. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax. 1997;52:67–71.
    1. Celli BR, Cote CG, Marin JM, Casanova C, Montes de OM, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:1005–1012. doi: 10.1056/NEJMoa021322.
    1. Celli BR, Calverley PM, rennard SI, Wouters EF, Agusti A, Anthonisen N, et al. Proposal for a multidimensional staging system for chronic obstructive pulmonary disease. Respir Med. 2005;99:1546–1554. doi: 10.1016/j.rmed.2005.03.019.
    1. Steyerberg EW, Borsboom GJ, van Houwelingen HC, Eijkemans MJ, Habbema JD. Validation and updating of predictive logistic regression models: a study on sample size and shrinkage. Stat Med. 2004;23:2567–2586. doi: 10.1002/sim.1844.
    1. Aaron SD, Fergusson D, Marks GB, Suissa S, Vandemheen KL, Doucette S, et al. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax. 2008;63:122–128. doi: 10.1136/thx.2007.082636.
    1. Langsetmo L, Platt RW, Ernst P, Bourbeau J. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med. 2008;177:396–401. doi: 10.1164/rccm.200708-1290OC.
    1. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54:581–586.
    1. Ackermann-Liebrich U, Kuna-Dibbert B, Probst-Hensch NM, Schindler C, Felber DD, Stutz EZ, et al. Follow-up of the Swiss Cohort Study on Air Pollution and Lung Diseases in Adults (SAPALDIA 2) 1991–2003: methods and characterization of participants. Soz Praventivmed. 2005;50:245–263. doi: 10.1007/s00038-005-4075-5.
    1. Puhan MA, Behnke M, Frey M, Grueter T, Brandli O, Lichtenschopf A, et al. Self-administration and interviewer-administration of the German Chronic Respiratory Questionnaire: instrument development and assessment of validity and reliability in two randomised studies. Health Qual Life Outcomes. 2004;2:1. doi: 10.1186/1477-7525-2-1.
    1. Puhan MA, Behnke M, Laschke M, Lichtenschopf A, Brandli O, Guyatt GH, et al. Self-administration and standardisation of the chronic respiratory questionnaire: a randomised trial in three German-speaking countries. Respir Med. 2004;98:342–350. doi: 10.1016/j.rmed.2003.10.013.
    1. Schunemann HJ, Puhan M, Goldstein R, Jaeschke R, Guyatt GH. Measurement properties and interpretability of the Chronic respiratory disease questionnaire (CRQ) COPD. 2005;2:81–89.
    1. Puhan MA, Behnke M, Devereaux PJ, Montori VM, Braendli O, Frey M, et al. Measurement of agreement on health-related quality of life changes in response to respiratory rehabilitation by patients and physicians – a prospective study. Respir Med. 2004;98:1195–1202. doi: 10.1016/j.rmed.2004.04.011.
    1. Puhan MA, Guyatt GH, Montori VM, Bhandari M, Devereaux PJ, Griffith L, et al. The standard gamble demonstrated lower reliability than the feeling thermometer. J Clin Epidemiol. 2005;58:458–465. doi: 10.1016/j.jclinepi.2004.07.010.
    1. Torrance GW, Feeny D, Furlong W. Visual analog scales: do they have a role in the measurement of preferences for health states? Med Decis Making. 2001;21:329–334.
    1. Snaith RP. The Hospital Anxiety And Depression Scale. Health Qual Life Outcomes. 2003;1:29. doi: 10.1186/1477-7525-1-29.
    1. Puhan MA, Frey M, Buchi S, Schunemann HJ. The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease. Health Qual Life Outcomes. 2008;6:46. doi: 10.1186/1477-7525-6-46.
    1. Stel VS, Smit JH, Pluijm SM, Visser M, Deeg DJ, Lips P. Comparison of the LASA Physical Activity Questionnaire with a 7-day diary and pedometer. J Clin Epidemiol. 2004;57:252–258. doi: 10.1016/j.jclinepi.2003.07.008.
    1. Ozalevli S, Ozden A, Itil O, Akkoclu A. Comparison of the Sit-to-Stand Test with 6 min walk test in patients with chronic obstructive pulmonary disease. Respir Med. 2007;101:286–293. doi: 10.1016/j.rmed.2006.05.007.
    1. Biobanken: Gewinnung, Aufbewahrung und Nutzung von menschlichem biologischem Material, medizinisch-ethische richtlinien und empfehlungen. 2006.
    1. Efron B, Hastie T, Johnstone I, Tibshirani R. Least angle regression: rejoinder. The Annals of Statistics. 2004;32:494–499.
    1. Harrell FE., Jr . Regression Modeling Strategies. New York, USA: Springer; 2001.
    1. Royston P, Sauerbrei W. Multivariable Model-building. West Sussex, England: Wiley; 2008.
    1. Copas JB, Long T. Estimating the residual variance in orthogonal regression with variable selection. The Statistician. 1991;40:51–59. doi: 10.2307/2348223.
    1. Tibshirani R. Regression Shrinkage and selection via the lasso. Journal of the Royal Statistical Society, Series B. 1996;58:267–288.
    1. Harrell FE, Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361–387. doi: 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>;2-4.
    1. Sullivan LM, Massaro JM, D'Agostino RB., Sr Presentation of multivariate data for clinical use: The Framingham Study risk score functions. Stat Med. 2004;23:1631–1660. doi: 10.1002/sim.1742.
    1. Reilly BM, Evans AT. Translating clinical research into clinical practice: impact of using prediction rules to make decisions. Ann Intern Med. 2006;144:201–209.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner